USOO9605O14B2 (12) United States Patent (10) Patent No.: US 9,605,014 B2 Woods et al. (45) Date of Patent: Mar. 28, 2017 (54) GLYCOMIMETICS TO INHIBIT C07H 19/01 (2013.01); C07H 19/02 PATHOGEN-HOST INTERACTIONS (2013.01); C07H 19/04 (2013.01); C07H 19/24 (2013.01); G06F 19/10 (2013.01) (71) Applicants: UNIVERSITY OF GEORGIA (58) Field of Classification Search RESEARCH FOUNDATION, INC., None Athens, GA (US); NATIONAL See application file for complete search history. UNIVERSITY OF IRELAND, GALWAY, Galway (IE): (56) References Cited GLYCOSENSORS AND DLAGNOSTICS, LLC., Athens, GA U.S. PATENT DOCUMENTS (US) 5,637,569 A * 6/1997 Magnusson ........ A61K 47/4833 (72) Inventors: Robert J. Woods, Athens, GA (US); 514/25 6,245,902 B1 6/2001 Linhardt et al. Paul V. Murphy, Galway (IE); Loretta 6,664,235 B1 12/2003 Kanie et al. Yang, San Diego, CA (US); Hannah 2006/0173199 A1 8/2006 Hong et al. M. K. Smith, Clare (IE); Jenifer 2011/O257032 A1 10/2011 Sasisekharan et al. Hendel, Alymer (CA) FOREIGN PATENT DOCUMENTS (73) Assignees: University of Georgia Research Foundation, Inc., Athens, GA (US); WO WO 98.31697 A1 6, 1998 National University of Ireland, WO WO 2012, 118928 A2 9, 2012 Galway, Galway (IE); Glycosensors and Diagnostics, LLC., Athens, GA OTHER PUBLICATIONS (US) Itzstein, Mark von, Nature Reviews, “The war against influenza: (*) Notice: Subject to any disclaimer, the term of this discovery and development of sialidase inhibitors', 2007, vol. 6, pp. patent is extended or adjusted under 35 967-974 U.S.C. 154(b) by 112 days. International Patent Application No. PCT/US2013/031238, filed Mar. 14, 2013; Written Opinion, issued May 30, 2013; 8 pages. (21) Appl. No.: 14/385,312 International Patent Application No. PCT/US2013/031238, filed Mar. 14, 2013; International Search Report, issued May 30, 2013; (22) PCT Filed: Mar. 14, 2013 4 pages. International Patent Application No. PCT/US2013/031238, filed (86). PCT No.: PCT/US2O13/031238 Mar. 14, 2013; International Preliminary Report on Patentability, issued Sep. 16, 2014; 10 pages. S 371 (c)(1), Angström et al., “Delineation and comparison of ganglioside (2) Date: Sep. 15, 2014 binding epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for overlapping epitopes' Proc (87) PCT Pub. No.: WO2013/138563 Natl AcadSci USA, 1994; 91(25): 11859-63. Babai et al., “New fimbrial gene cluster of S-fimbrial adhesin PCT Pub. Date: Sep. 19, 2013 family” Infect Immun, 2000; 68(10):5901-7. Backenson, “Borrelia burgdorferi shows specificity of binding to (65) Prior Publication Data glycosphingolipids” Infect Immun, 1995; 63(8):2811-7. US 2015/OO72952 A1 Mar. 12, 2015 Blumenschein et al., “Atomic resolution insight into host cell recognition by Toxoplasma gondii” EMBO.J. 2007; 26(11):2808 20. Related U.S. Application Data Case et al., “The Amber biomolecular simulation programs' J (60) Provisional application No. 61/611,890, filed on Mar. Computat Chem, 2005; 26:1668-88. 16, 2012. (Continued) (51) Int. Cl. Primary Examiner — Layla Berry C07H 17/04 (2006.01) Assistant Examiner — Bahar Craigo C07H 15/20 (2006.01) (74) Attorney, Agent, or Firm — Mueting, Raasch & C07H 17/02 (2006.01) Gebhardt, PA. C07H 19/01 (2006.01) C07H 19/02 (2006.01) (57) ABSTRACT C7H 9/04 (2006.01) The present invention relates to novel glycomimetic com C7H 9/24 (2006.01) pounds that are rationally designed to inhibit the binding of C7H I5/04 (2006.01) various pathogens to cell Surface sialylated galactose and CO7D 455/02 (2006.01) methods of use thereof. Specifically sialic acid glycosides G06F 9/10 (2011.01) and C-glycosides are disclosed that form a lactam ring (52) U.S. Cl. structure or a cyclic etherfamine ring structure with the CPC ........... C07H 17/04 (2013.01); C07D455/02 adjacent monosaccharide residue. (2013.01); C07H 15/04 (2013.01); C07H 15/20 (2013.01); C07H 17/02 (2013.01); 21 Claims, 13 Drawing Sheets US 9,605,014 B2 Page 2 (56) References Cited Biarnes et al., “Substrate distortion in the Michaelis complex of Bacillus 1,3-1,4-beta-glucanase. Insight from first principles molecular dynamics simulations.” J Biol Chem, 2006, 281: 1432-41. OTHER PUBLICATIONS Bloom et al., "Permissive Secondary Mutations Enable the Evolu tion of Influenza Oseltamivir Resistance.” Science, 2010; Delorme et al., "Glycosphingolipid binding specificities of rotavi 328(5983): 1272-5. rus: identification of a sialic acid-binding epitope,” J Virol, 2001; Bosques et al., "Effects of glycosylation on peptide conformation: 75(5):2276-87. a Synergistic experimental and computational study,” J Am Chem Dugan et al., “An N-linked glycoprotein with alpha(2,3)-linked Soc, Jul 14, 2004; 126(27):8421-5. sialic acid is a receptor for BK virus,” J Virol, 2005; 79(22): 14442 Busse et al., "Galactose-Phosphonates as Mimetics of the 5. Sialyltransfer by Trypanosomal Sialidases,” J Carbohydrate Chem, Fadda and Woods, "Molecular simulations of carbohydrates and Jun. 1, 2007; 26(3): 159-194. protein-carbohydrate interactions: motivation, issues and pros Chagnault et al., "Synthesis of somatostatin mimetics based on pects.” Drug Discov Today, Aug. 2010; 15(15-16):596-609. 1-deoxynojirimycin.” ChemMedChem, Jul. 2008; 3(7): 1071-6. Ford et al., "Molecular dynamics simulations of galectin-1- Chandrasekaran et al., "Glycan topology determines human adap oligosaccharide complexes reveal the molecular basis for ligand tation of avian H5N1 virus hemagglutinin.” Nat Biotechnol, Jan. diversity.” Proteins, Nov. 1, 2003: 53(2):229-40. 2008; 26(1): 107-13. Gonzalez-Outeirino et al., “Reconciling solvent effects on rotamer Charvatova et al., “Quantifying Protein Interface Footprinting by populations in carbohydrates-Ajoint MD and NMR analysis” Can Hydroxyl Radical Oxidation and Molecular Dynamics Simulation: J Chem, Apr. 1, 2006;84(4):569-79. Application to Galectin-1.” J Am Soc Mass Spectrom, Nov. 2008, Ha et al., "X-ray structures of H5 avian and H9 Swine influenza 19(11): 1692-705. virus hemagglutinins bound to avian and human receptor analogs' Cheng et al., "Convenient temporary methyl imidate protection of Proc Natl AcadSci USA, Sep. 25, 2001; 98(20): 11181-6. N-acetylglucosamine and glycosylation at O-4.” J Org Chem, Oct. Ha et al., "X-ray structure of the hemagglutinin of a potential H3 3, 2008; 73(19):7574-9. avian progenitor of the 1968 Hong Kong pandemic influenza virus.” Chervenak et al., "Calorimetric analysis of the binding of lectins Virology, May 10, 2003; 309(2): 209-18. with overlapping carbohydrate-binding ligand specificities.” Idanpään-Heikkilä et al., “Oligosaccharides interfere with the estab Biochem, Apr. 25, 1995; 34(16):5685-95. lishment and progression of experimental pneumococcal pneumo Connor et al., "Receptor specificity in human, avian, and equine H2 nia.” J Infect Dis, 1997: 176(3):704-12. and H3 influenza virus isolates.” Virology, Nov. 1994: 205(1): Itzstein, "The war against influenza: discovery and development of 17-23. sialidase inhibitors' Nature reviews—drug discovery, Dec. 2007; Cox et al., "Global epidemiology of influenza: past and present.” 6:967-74. retrieved on Aug. 5, 2016 from the Internet. Retrieved Annu Rev Med. 2000; 51:407-21. from the Internet:<URL:http://www.cmbi.ru.nl/edu/bioinfa/articles/ Cronin et al., “Novel synthesis of castanospermine and pdf cmc nrd2400 Itzstein NRDD07.pdf>; 8 pages. 1-epicastanospermine.” Org Lett, Jun. 23, 2005; 7(13):2691-3. Jorgensen, "Efficient drug lead discovery and optimization.” Acc Dam et al., "Thermodynamic studies of lectin-carbohydrate inter Chem Res, Jun. 16, 2009:42(6):724-33. actions by isothermal titration calorimetry,” Chem Rev. Feb. 2002: Kadirvelraj et al., “Understanding the bacterial polysaccharide 102(2):387-429. antigenicity of Streptococcus agalactiae versus Streptococcus Danieli et al., "Selective protecting group manipulations on the pneumoniae.” Proc Natl Acad Sci U S A. May 23, 1-deoxynojirimycin scaffold.” Tetrahedron, 2007; 63:6827-34. 2006; 103(21): 8149-54. Desoky et al., “Preparation of trifluoroethyl- and phenyl-protected Kirschner et al., "GLYCAM06: a generalizable biomolecular force sulfates using sulfuryl imidazolium salts.” Tetrahedron, 2011, field. Carbohydrates.”J Comput Chem, 2008; 29(4):622-55. 67(6): 1281-7. Lin et al., “The hemagglutinin structure of an avian H1N1 influenza European Centre for Disease Prevention and Control, “Emergence A virus,” Virology, Sep. 15, 2009:392(1): 73-81. of Seasonal Influenza Viruses Type A/H1N1 with Oseltamivir Newhouse et al., “Mechanism of glycan receptor recognition and Resistance in Some European Countries at the Start of the 2007-8 Specificity Switch for avian, Swine, and human adapted influenza Influenza Season' Interim ECDC Risk Assessment, Jan. 27, 2008; virus hemagglutinins: a molecular dynamics perspective,” J Am Retrieved from the Internet on Oct. 17, 2016: <URL:http://ecdc. Chem Soc, Dec. 2, 2009; 131(47): 1743.0-42. europa.eu/en/press/Press%20Releases/080127 PR Risk asses Ofek et al., "Anti-adhesion therapy of bacterial diseases: prospects ment.pdf>; 11 pgs. and problems.” FEMS Immunol Med Microbiol, Oct. 15, 2003; Epand et al., "The role of the ganglioside GDla as a receptor for 38(3):181-91. Sendai virus.” Biochem, Jan. 24, 1995; 34(3):1084-9. Roche et al., "Helicobacter pylori and complex gangliosides,'Infect Ernst et al., "From carbohydrate leads to glycomimetic drugs.” Nat Immun, 2004; 72(3): 1519-29. Rev Drug Discov, Aug. 2009; 8(8):661-77. Rogers and Snyder, "High affinity binding of tetanus toxin to Ferraris et al., "Mutations of neuraminidase implicated in mammalian brain membranes.” J Biol Chem, 1981; 256(5):2402-7. neuraminidase inhibitors resistance.' J Clin Virol, Jan. 2008; Skehel et al., “Receptor Binding and Membrane Fusion in Virus 41(1): 13-9. Entry: The Influenza Hemagglutinin' Annu Rev. Biochem, 2000; Gamblin et al., "The structure and receptor binding properties of the 69:531-69.